Canine melanoma: Combating a destructive and deadly tumor

Veterinary Medicine

Volumn 96, Issue 12, 2001, Pages 931-941

  Sulaimon, Shola S ^a   Kitchell, Barbara E ^a  

^a Veterinary Teaching Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0039896261     PISSN: 87507943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Todoroff, R.J.; Brodey, R.S.: Oral and pharyngeal neoplasia in the dog: A retrospective survey of 361 cases. JAVMA 175 (6):567-571; 1979.
2. Oliver, J.L.; Wolfe, L.G.; Antigen expression in canine tissues, recognized by monoclonal antibody generated against canine melanoma cells. AJVR 53 (1):123-128; 1992.
3. Cotchin, E.: Melanotic tumors of dogs. J. Comp. Pathol. 65:115-128; 1955.
4. Brodey, R.S.: A clinical and pathologic study of 130 neoplasms of the mouth and pharynx in the dog. AJVR 21:787-812; 1960.
5. Cohen, D. et al.: Epidemiologic aspects of oral and pharyngeal cancer in dogs. AJVR 25:1776-1779; 1964.
6. Conroy, J.D.: Melanocytic tumors of domestic animals with special reference to dogs. Arch. Dermatol. 96 (4):372-380; 1967.
7. Dorn, C.R.; Priester, W.A.: Epidemiologic analysis of oral and pharyngeal cancer in dogs, cats, horses, and cattle. JAVMA 169 (11):1202-1206; 1976.
8. MacVean, D.W. et al.: Frequency of canine and feline tumors in a defined population. Vet. Pathol. 15 (6):700-715; 1978.
9. Bostock, D.E.: Prognosis after surgical excision of canine melanomas. Vet. Pathol. 16 (1):32-40; 1979.
10. Pulley, L.T.; Stannard, A.A.: Tumors of the skin and soft tissues. Tumors in Domestic Animals, 3rd Ed. (J.E. Moulton, ed.). University of California Press, Los Angeles, 1990; pp 755-782.
11. Dorn, C.R. et al.: Survey of animal neoplasms in Alameda and Contra Costa Counties, California II. Cancer morbidity in dogs and cats from Alameda County. J. Natl. Cancer Inst. 40 (2):307-318; 1968.
12. Brodey, R.S.: A clinico-pathologic study of 20 cases of oral and pharyngeal cancer in the dog. Newer Knowledge About Dogs. Gaines Veterinary Symposium, New York, 1961; pp 5-11.
13. Mulligan, R.M.: Melanoblastic tumors in the dog. JAVMA 188:345-351; 1961.
14. Wilcock, B.P.; Peiffer, R.L. Jr.: Morphology and behavior of primary ocular melanomas in 91 dogs. Vet. Pathol. 23 (4):418-424; 1986.
15. Diters, R.W. et al.: Primary ocular melanoma in dogs. Vet. Pathol. 20 (4):379-395; 1983.
16. Ryan, A.M.; Diters, R.W.: Clinical and pathologic features of canine ocular melanomas. JAVMA 184 (1):60-67; 1984.
17. Bussanich, N.M. et al.: Canine uveal melanomas: Series and literature review. JAAHA 23:415-422; 1987.
18. Marino, D.J. et al.: Evaluation of dogs with digit masses: 117 cases (1981-1991). JAVMA 207 (6):726-728; 1995.
19. Aronsohn, M.G.; Carpenter, J.L.: Distal extremity melanocytic nevi and malignant melanomas in dogs. JAAHA 26:605-612; 1990.
20. Collins, B.K. et al.: Biologic behavior and histologic characteristics of canine melanoma. Prog. Vet. Comp. Ophthalmol. 3:135-140; 1993.
21. Blackwood, L.; Dobson, J.M.: Radiotherapy of oral malignant melanomas in dogs. JAVMA 209 (1):98-102; 1996.
22. Modiano, J.F. et al.: The molecular basis of canine melanoma: Pathogenesis and trends in diagnosis and therapy. J. Vet. Intern. Med. 13 (3):163-174; 1999.
23. Goldschimdt, M.H.: Benign and malignant melanocytic neoplasms of domestic animals. Am. J. Dermatopathol. 7 (suppl.): 203-212; 1985.
24. Hahn, K.A. et al.: Canine oral malignant melanoma; Prognostic utility of an alternative staging system. J. Am. Anim. Pract. 35:251-256; 1994.
25. Vail, D.M.; Withrow, S.J.: Tumors of the skin and subcutaneous tissues. Small Animal Clinical Oncology, 2nd Ed. (S.J. Withrow; E.G. MacEwen, eds.). W.B. Saunders, Philadelphia, Pa. 1996; pp 167-191.
26. Dubielzig, R.R.: Ocular neoplasia in small animals. Vet. Clin. North Am. (Small Anim. Pract.) 20 (3):837-848; 1990.
27. Minami, T.; Patnaik, A.K.: Malignant anterior uveal melanoma with diffuse metastasis in a dog. JAVMA 201 (12):1894-1896; 1992.
28. Passey, R.D.: Experimental tar tumors in dogs. J. Pathol. Bacteriol. 47:349-351; 1938.
29. Withrow, S.J.; MacEwen, E.G.: Immunology and biologic therapy of cancer. Small Animal Clinical Oncology, 2nd Ed. (S.J. Withrow; E.G. MacEwen, eds.). W.B. Saunders, Philadelphia, Pa., 1996; pp 99-116.
30. Weiss, E.; Frese, K.: Tumours of the skin. Bull. World Health Organ. 50 (1-2):79-100; 1974.
31. Owen, L.N.: TNM classification of tumors of domestic animals. World Health Organ. Bull.: 21-25; 1980.
32. Breslow, A.: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann. Surg. 172 (5):902-908; 1970.
33. Clark, W.H.: Tumour progression and the nature of cancer. Br. J. Cancer. 64 (4):631-644; 1991.
34. Schwartz, P.D. et al.: Mandibular resection as a treatment for oral cancer in 81 dogs. JAAHA 27:601-610; 1991.
35. Ahern, T.E. et al.: Overexpression of c-erbB-2 and c-myc but not c-ras, in canine melanoma cell lines, is associated with metastatic potential in nude mice. Anticancer Res. 13 (5A):1365-1371; 1993.
36. Bolon, B. et al.: Characteristics of canine melanomas and comparison of histology and DNA ploidy to their biologic behavior. Vet. Pathol. 27 (2):96-102; 1990.
37. Salisbury, S.K.; Lant, G.G.: Long-term results of partial mandibulectomy for treatment of oral tumors in 30 dogs. JAAHA 24:285-294; 1988.
38. Harvey, H.J. et al.: Prognostic criteria for dogs with oral melanoma. JAVMA 178 (6): 580-582; 1981.
39. Wallace, J. et al.: Hemimaxillectomy for the treatment of oral tumors in 69 dogs. Vet. Surg. 21 (5):337-341; 1992.
40. Ogilvie, G.K.; Moore, A.S.: Oral malignant melanoma in dogs. Managing the Veterinary Cancer Patient: A Practice Manual, 2nd Ed. (G.K. Ogilvie; A.S. Moore, eds.). Veterinary Learning Systems, Trenton, N.J., 1996; pp 332-336.
41. Kosovsky, J.K. et al.: Results of partial mandibulectomy for treatment of oral tumors in 142 dogs. Vet. Surg. 20 (6):397-401; 1991.
42. White, R.A.S.: Mandibulectomy and maxillectomy in the dog. Long term survival in 100 cases. J. Small Anim. Pract. 32:69-74; 1991.
43. Nasisse, M.P. et al.: Neodymium: YAG laser treatment of primary canine intraocular tumors. Prog. Vet. Comp. Ophthalmol. 3:152-157; 1993.
44. Gelatt, K.N. et al.: Primary iridal pigmented masses in three dogs. JAAHA 15:339-344; 1979.
45. Hornsey, S.: The radiation response of human malignant melanoma cells in vitro and in vivo. Cancer Res. 32 (3):650-651; 1972.
46. Hornsey, S.: The relationship between total dose, number of fractions and fraction size in the response of malignant melanoma in patients. Br. J. Radiol. 51:905-909; 1978.
47. Bentzen, S.M. et al.: Clinical radiobiology of malignant melanoma. Radiother. Oncol. 16 (3): 169-182; 1989.
48. Bateman, K.E. et al.: 0-7-21 radiation therapy for the treatment of canine oral melanoma. J. Vet. Intern. Med. 8 (4):267-272; 1994.
49. Guptill, L. et al.: Personal communication, Annual Veterinary Cancer Society Conference, Columbus, Ohio, 1993.
50. Kraegel, S.A.; Page, R.L.: Advances in platinum compound chemotherapy. Current Veterinary Therapy XI Small Animal Practice (R.W. Kirk; J.D. Bonagura, eds.). W.B. Saunders, Philadelphia, Pa., 1992; pp 395-399.
51. Kitchell, B.E. et al.: Intralesional implants for treatment of primary oral malignant melanoma in dogs. JAVMA 204 (2):229-236; 1994.
52. Hemmila, M.R.; Chang, A.E.: Clinical implications of the new biology in the development of melanoma vaccines. J. Surg. Oncol. 70 (4):263-274; 1999.
53. MacEwen, E.G. et al.: Adjuvant therapy for melanoma in dogs: Results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 5 (12):4249-4258; 1999.
54. MacEwen, E.G. et al.: Canine oral melanoma: Comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest. 4 (5):397-402; 1986.
55. Dow, S.W. et al.: In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J. Clin. Invest. 101 (11):2406-2414; 1998.
56. Rosenberg, S.A. et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer with high-dose bolus interleukin 2. JAMA 271 (12):907-913; 1994.
57. Strome, S.E. et al.: Immunobiologic effects of cytokine gene transfer of the B16-BL6 melanoma. Arch. Otol. 119:1289-1295; 1993.
58. Dranoff, G. et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90 (8):3539-3543; 1993.
59. Hogge, G.S. et al.: Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell line and normal dogs. Cancer Gene Ther. 6 (1):26-36; 1999.
60. Quintin-Colonna, F. et al.: Gene therapy of spontaneous canine melanoma and feline flbrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther. 3 (12):1104-1112; 1996.